🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

RecruitingNAAges 18 Years - anyAllShahid Beheshti University of Medical Sciences
NCT07033858 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All Kidney transplant recipients Exclusion Criteria: * Kidney-Pancreas transplant BMI\>30 cPRA\>0%
💊

What it tests

  • Rapamune Pill
📍

Where

1 site
Nooshin Dalili
Tehran, Iran
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy